Latest reports
The ESG Performance Report includes our performance across our six environmental, social and governance (ESG) priority areas, and includes ESG data for current and previous years. Within the Responsible Business section of our Annual Report, we provide a summary and highlights of our progress in 2022.
Our position on
Learn more about our views and our practices across a range of access, R&D, intellectual property, health security and environment issues here.
ESG reports archive
Search our archive of responsible business reports and resources dating back to 2002.
ESG ratings performance
Detailed below is how we perform in key ESG ratings.
| External benchmarking | Current rating |
Previous rating |
Relative to peers |
|---|---|---|---|
| S&P Global Corporate Sustainability Assessment | 86/100 | 88/100 | 2nd in the pharmaceutical industry group |
| Access to Medicines Index | 4.06 | 4.23 | 1st in the Index |
| Antimicrobial Resistance Benchmark | 84% | 86% | Leader |
| CDP Climate change | A- | A- | |
| CDP Water security | B | B | |
| CDP Forests (palm oil) | A | B | |
| CDP Forests (timber) | B | B | |
| CDP Supplier engagement rating | Leader | Leader | |
| Sustainalytics | 18.8 Low risk rating | 18.9 Low risk rating | 3/473 subindustry group. A lower score represents lower risk. |
| MSCI | AA | AA | |
| Moody's ESG solutions | 61 | 61 | 2nd in the pharmaceutical sector |
| ISS Corporate Rating | B+ | B | |
| FTSE4Good | Member of FTSE4Good Index since 2004 | Member of FTSE4Good Index since 2004 |
Scores as at 2 March 2023
Disclosure
Charitable grants
We publish our charitable giving data in our Annual Report and ESG performance summary each year. We are further increasing transparency by publishing details of our individual charitable grants over £10,000 ($15,000). Details of the grants are available in the Charitable Grants report 2022 (PDF 417.1KB).
In addition to the grants of £10,000 or more declared here, GSK discloses grants to US-based non-profit organisations that foster increased understanding of scientific, clinical, and healthcare issues and contribute to improving patient care.
Trade association memberships
GSK is a member of many trade and industry associations that primarily represent pharmaceutical, consumer products and vaccine businesses at the national, regional and international levels.
Trade Association Membership 2022 (PDF - 100.8KB)Patient organisation funding
Patient organisations – non-profit organisations founded by patients, care-givers, family members and health professionals – are important stakeholders for GSK.
They engage with healthcare providers, governments, the media, and patients to promote improved treatment and services for patients. They also campaign on issues that affect patients’ and care-givers’ lives, including increasing access to quality medicines, services and information on disease. Some carry out research into the causes of and potential treatments for specific conditions.
Listed below are the patient organisations that we support:
1. Pan European
During 2019-2021, we provided financial support to the following pan European patient organisations:
EUROPA DONNA - The European Breast Cancer Coalition (PDF-343KB)
European Cancer Patient Coalition (ECPC) (PDF-206KB)
European Federation of Allergy and Airways Disease Patients Association (PDF-677KB)
European Network of Gynaecological Cancer Advocacy Groups (ENGAGe) (PDF-210KB)
European Patients' Forum (EPF) (PDF-196KB)
Myeloma Patients Europe (PDF-257KB)
Pulmonary Hypertension Association Europe (PDF-55.9KB)
Sarcoma Patients EuroNet (SPAEN) (PDF-343KB)
2. National European
Details of funding provided to patient organisations across Europe can be found on the relevant market website. Where no market website currently exists, and for those GSK local operating companies that supported patient organisations in 2021, the information is either published directly on this page or in a booklet available from the local office.
Markets with websites:
Markets without websites:
During 2021, we provided support to the following UK patient organisations:
Asthma UK and British Lung Foundation Partnership (PDF-206KB)
Ovarian Cancer Action (PDF-200KB)
Somerset and Wessex Eating Disorder Association (PDF-202KB)
Target Ovarian Cancer (PDF-203KB)
During 2020, we provided support to the following UK patient organisations:
PAG disclosure 2020 (PDF-627KB)
During 2019, we provided support to the following UK patient organisations:
PAG disclosure 2019 (PDF-675KB)
GSK also provides funding to support UK community healthcare charities through the GSK IMPACT Awards, in partnership with The King’s Fund. This annual programme recognises and promotes excellence in community healthcare, providing funding and training to help strengthen the award winners’ current management plans and support their future aspirations.
3. Emerging Markets and Intercontinental
During 2021 we provided funding to the following emerging markets and intercontinental patient organisations:
Markets with websites:
Markets without websites:
4. Global
During 2019-2021, we provided financial support to the following global patient organisations:
Global Asthma and Allergy Patient Platform (GAAPP) (PDF-218KB)
International Alliance of Patient Organisations (IAPO) (PDF-210KB)
International Gynecologic Cancer Society (IGCS) (PDF-210KB)
International Myeloma Foundation (IMF) (PDF-264KB)
Meningitis Research Foundation (MRF) (PDF-212KB)
Engaging with healthcare professionals
We are committed to disclosing the payments we make, as we work together with healthcare professionals. Find our disclosure reports at Engaging with healthcare professionals.
